Skip to content
Clinical Trials – home

Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania

Verified siteinfo

Italy Via Santa Sofia 78, 95123 Catania, Italy

  • 123 trials recruiting
  • Non-small cell lung cancer · Hidradenitis · Plasma cell myeloma
  • Adults and children

About Specializations

Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania in Catania, Italy specialises in clinical trials of conditions such as Non-small cell lung cancer, Hidradenitis, Plasma cell myeloma, Idiopathic pulmonary fibrosis, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory Infections and Pulmonary Diseases

The medical center is at the forefront of research in respiratory infections and pulmonary diseases, focusing on innovative treatments and preventive measures. The center's work in this area is crucial for developing new therapies that improve patient outcomes and quality of life.

  • Recurrent Lower Respiratory Tract Infections (RLRTIs)
  • Pulmonary Sarcoidosis
  • Idiopathic Pulmonary Fibrosis (IPF)

Through rigorous clinical trials, the center is advancing the understanding of these conditions and exploring novel therapeutic approaches.

Oncology and Hematology

Specializing in oncology and hematology, the center is dedicated to pioneering research in cancer treatment, particularly in challenging cases of relapse and refractory conditions. The institution's commitment to innovation is evident in its diverse clinical trials aimed at improving survival rates and patient care.

  • Non-Small Cell Lung Cancer (NSCLC)
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Multiple Myeloma

The center's research is instrumental in developing targeted therapies and personalized medicine strategies.

Autoimmune and Inflammatory Diseases

With a strong focus on autoimmune and inflammatory diseases, the center is leading efforts to understand and treat complex conditions that affect millions worldwide. The research conducted here is vital for discovering new treatment modalities that can significantly alter disease progression.

  • Systemic Lupus Erythematosus (SLE)
  • Dermatomyositis
  • Hidradenitis Suppurativa (HS)

By exploring the underlying mechanisms of these diseases, the center aims to develop more effective and safer therapeutic options.

Neurology and Neurodegenerative Disorders

The center is a leader in neurology and neurodegenerative disorders, focusing on innovative research to combat these debilitating conditions. The institution's work is crucial for advancing the understanding and treatment of neurological diseases.

  • Multiple Sclerosis (MS)
  • Multiple System Atrophy (MSA)

Through cutting-edge research, the center is paving the way for new therapies that can improve patient outcomes and quality of life.

Cardiovascular and Metabolic Disorders

Focusing on cardiovascular and metabolic disorders, the center is dedicated to advancing research in these critical areas. The institution's efforts are aimed at developing new treatments that can effectively manage and prevent these widespread health issues.

  • Acute Coronary Syndrome
  • Sickle Cell Disease (SCD)

The center's research is essential for understanding the complex interactions between these disorders and developing comprehensive treatment strategies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Santa Sofia 7895123 CataniaItaly
Recruiting now
123 trials
Conditions studied
163
Partner status
Verified site

More sites in CataniaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

309 clinical trials

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB
Countries:ItalyItaly
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Evaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

Vitiligo

Recruiting

Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.